West Pharma (WST) Tops Q1 EPS by 18c; Bumps Guidance Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $392.15 -0.48%
Revenue Growth %: +2.8%
Financial Fact:
Dividends declared per share: 0.13
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +2.8%
Financial Fact:
Dividends declared per share: 0.13
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
West Pharma (NYSE: WST) reported Q1 EPS of $2.30, $0.18 better than the analyst estimate of $2.12. Revenue for the quarter came in at $720 million versus the consensus estimate of $720.92 million.
GUIDANCE:
West Pharma sees FY2022 EPS of $9.30-$9.45, versus the prior range of $9.20-$9.35 and the consensus of $9.28.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- AI-powered cyber threats light a fire under cybersecurity stocks
- SLM (SLM) Misses Q3 EPS by 36c; lowers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
